Clinical Trials Logo

Ocular Hypertension clinical trials

View clinical trials related to Ocular Hypertension.

Filter by:

NCT ID: NCT06455683 Not yet recruiting - Ocular Hypertension Clinical Trials

The A D A G I O Study

Start date: June 2024
Phase:
Study type: Observational

This study aims to investigate the effect of different types of glaucoma surgery on aqueous dynamics parameters (IOP, aqueous flow rate, trabecular outflow facility and uveoscleral outflow) in patients with uncontrolled open angle glaucoma or ocular hypertension (OHT)

NCT ID: NCT06441643 Not yet recruiting - Ocular Hypertension Clinical Trials

Next Generation Rocklatan

Start date: September 2024
Phase: Phase 2
Study type: Interventional

The purpose of this two-stage clinical trial is to assess the safety and hypotensive efficacy of AR-17043 and PG043 ophthalmic solutions in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

NCT ID: NCT06394973 Not yet recruiting - Glaucoma Clinical Trials

Efficacy and Safety Assessment of T4090 Ophthalmic Solution Versus Rhopressa® Ophthalmic Solution in Patients With Open-angle Glaucoma or Ocular Hypertension

Start date: July 2024
Phase: Phase 2
Study type: Interventional

The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution

NCT ID: NCT06388096 Recruiting - Glaucoma, Suspect Clinical Trials

CLAD Deconvolved PERG Responses in Glaucoma Patients

Start date: June 1, 2023
Phase: N/A
Study type: Interventional

Glaucoma is a progressive disease resulting in blindness. Determining the onset of the disease is critical so patients may obtain treatment to preserve useful vision. This study will collect data from a population of glaucoma suspects (with positive factors for the disease but with normal vision) along with a population of age matched controls using the pattern electroretinogram (PERG) and other standard eye tests for glaucoma. The PERG measures the function of retinal ganglion cells (RGCs) which come together to form the optic nerve. RGCs may become dysfunctional before dying. The Continuous loop deconvolution technique (CLAD) will be used to extract transient PERG responses in both glaucoma suspects and age matched controls. All patients will be monitored with PERG, Optic Coherence Tomography (OCT) and other ancillary tests over 2 years. CLAD will be compared with conventional techniques of monitoring glaucoma (standard PERG, OCT, visual field etc) to see if the CLAD is better at distinguishing between glaucoma suspects and controls.

NCT ID: NCT06267274 Not yet recruiting - Ocular Hypertension Clinical Trials

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Start date: April 1, 2024
Phase: Phase 1
Study type: Interventional

A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study

NCT ID: NCT06266351 Not yet recruiting - Glaucoma Clinical Trials

EVALUATION OF CATS TONOMETER PRISM IN LASIK SUBJECTS

Start date: February 12, 2024
Phase:
Study type: Observational

The CATS Tonometer prism clinical study is intended to determine repeatability of intraocular pressure measurement in human corneas which have undergone a LASIK procedure when compared to a standard Goldmann prism, validating the human LASIK eye findings comparing CATS Tonometer and Goldmann prisms to intracameral pressure in cadaver eyes.

NCT ID: NCT06249152 Recruiting - Glaucoma Clinical Trials

Qlaris Study of QLS-111 in Combination With a PGA for OAG and/or OHT Patients

Start date: April 21, 2024
Phase: Phase 2
Study type: Interventional

Qlaris Phase 2 clinical study investigating the safety, tolerability, and ocular hypotensive efficacy of QLS-111 in combination with latanoprost in open-angle glaucoma (OAG) and/or ocular hypertension (OHT) patients.

NCT ID: NCT06190028 Recruiting - Dry Eye Syndrome Clinical Trials

Evaluation of Performance and Safety of Carbopol 980 NF 0.2%- Based Medical Device in the Management of Patients With Glaucomar or Ocular Hypertension and Concomitant Dry Eye Syndrome on Multiple Long-term Topical Hypotensive Therapy

Start date: June 14, 2023
Phase: N/A
Study type: Interventional

The main aim of this investigation is to evaluate the effect of the preservative-free ophthalmic solution IRIDIUM® A gel on the ocular surface of patients with glaucoma or OHT and concomitant DES under multiple long-term topical hypotensive therapy for at least 6 months. The underlying assumption is that ophthalmic solutions as adjuvants for the management of IOP- or glaucoma-associated dry eye may induce a protection of the eye surface with consequent improvement of the symptoms and of the overall quality of life.

NCT ID: NCT06177678 Not yet recruiting - Ocular Hypertension Clinical Trials

A Randomized, Open-label, Active-controlled, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of TFC-003 in Patients With Primary Open-angle Glaucoma or Ocular Hypertension

Start date: February 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study was to explore the efficacy and safety of the weekly intraocular pressure change of the TFC-003 group and the dorzolamid/timolol combination group in patients with primary open-angle glaucoma or ocular hypertension.

NCT ID: NCT06152861 Recruiting - Ocular Hypertension Clinical Trials

Travoprost Ophthalmic Topical Cream for Open-angle Glaucoma or Ocular Hypertension

Start date: November 15, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to learn about the safety of Travoprost Ophthalmic Topical Cream and how well it works in lowering high intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). A low dose, medium dose and high dose of Travoprost Ophthalmic Topical Cream will be compared to timolol maleate ophthalmic solution, 0.5% and to travoprost ophthalmic solution, 0.004%.